Back to results
US 2010/0166750 A1Published application
Indications for Anti-IL-1 Beta Therapy
AssigneeNovartis AG
InventorsHermann Gram, Thomas Jung
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeNovartis AG
InventorsHermann Gram, Thomas Jung
Estimating the term…
This invention relates to a novel use of IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.
-3. (canceled)
A method of treating an auto-inflammatory syndrome in a patient in need thereof, comprising administering to said patient an effective amount of an IL-1beta binding molecule comprising an antigen binding site comprising at least one immunoglobulin heavy chain variable domain (VH) which comprises in sequence hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Val-Tyr-Gly-Met-Asn, said CDR2 having the amino acid sequence Ile-Ile-Trp-Tyr-Asp-Gly-Asp-Asn-Gln-Tyr-Tyr-Ala-Asp-Ser-Val-Lys-Gly, and said CDR3 having the amino acid sequence Asp-Leu-Arg-Thr-Gly-Pro;
A method of treating an auto-inflammatory syndrome in a patient in need thereof, comprising administering to said patient an effective amount of an IL-1beta binding molecule comprising both heavy (VH) and light chain (VL) variable domains in which said IL-1beta binding molecule comprises at least one antigen binding site comprising:
Dependencies are inferred from the claim text.